---
$id: https://graph.org.ai/products/commodity/51142525
$type: Product
source: UNSPSC
code: "51142525"
title: "Droxidopa"
class: "51142500"
classTitle: "Antiparkinson drugs"
family: "51140000"
familyTitle: "Central nervous system drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Droxidopa

**UNSPSC Code**: 51142525
**Class**: [Antiparkinson drugs](Antiparkinson drugs.mdx)
**Family**: [Central nervous system drugs](../Central nervous system drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiparkinsonian agent with the molecular formula C9H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7A92W69L7, chemically known as (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine but generally known as droxidopa, which bears US NIH Compound Identifier 3171. European Medicines Agency schedules Droxidopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06420MIG. The term DROXIDOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DROXIDOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droxidopa under HS 29225000 and SITC 51467. As of Q4 2014, DROXIDOPA remains the US FDA Preferred Term for this commodity. Droxidopa bears US NLM identifiers UMLS ID C0000378 and NCI Concept Code C73266. SMILES: OC(C(N)C(=O)O)C1CC(O)C(O)CC1.

